Entering text into the input field will update the search result below

MiNK Therapeutics A Bargain For Potential Cell Therapies

Jun. 23, 2022 10:56 AM ETMiNK Therapeutics, Inc. (INKT)AGEN1 Comment
William Meyers profile picture
William Meyers


  • iNKT cells have unique properties that could be therapeutic.
  • MiNK Therapeutics has shown it can both manufacture and engineer iNKT cells.
  • Preliminary data expected before year-end could push the stock price substantially higher.

Dentritic Cell activate T cells, trigger immune responses, they are responsible of cells protection of the body.

Design Cells/iStock via Getty Images

MiNK Therapeutics (NASDAQ:INKT) is a clinical-stage biotechnology company specializing in engineering immune system cells to provide therapies for cancers and other diseases. Initial enthusiasm for the stock, which had its IPO in October 2021 at $12 per

Data by YCharts

This article was written by

William Meyers profile picture
I provided stock and bond research and analysis to a small cap specialist investor, Lloyd Miller, from 2002 until his death in January 2018. For my own account I invest mainly in technology and biotechnology stocks. My technology and investment web site is openicon.com, where readers can view the notes I take to make decisions and to write articles for Seeking Alpha.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of INKT, SANA, AGEN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.